This is a U.S. news story, published by Yahoo, that relates primarily to Paxlovid news.
For more U.S. news, you can click here:
more U.S. newsFor more Paxlovid news, you can click here:
more Paxlovid newsFor more vaccine development news, you can click here:
more vaccine development newsFor more news from Yahoo, you can click here:
more news from YahooOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like this article about vaccine development, you might also like this article about
COVID vaccine. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest vaccination updates news, severe illness news, news about vaccine development, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
COVIDVerywell Health
•85% Informative
LB.1 is the latest COVID-19 subvariant to emerge in the U.S. Current rapid tests and treatments like Paxlovid are still effective, and updated vaccines in the fall should offer sufficient protection.
Older adults, pregnant people, and those who have underlying conditions are still at the highest risk of severe illness from COVID .
VR Score
85
Informative language
82
Neutral language
85
Article tone
formal
Language
English
Language complexity
56
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
medium-lived
External references
5
Source diversity
3
Affiliate links
no affiliate links